X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs NOVARTIS - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE NOVARTIS STRIDES PHARMA SCIENCE/
NOVARTIS
 
P/E (TTM) x 20.7 432.2 4.8% View Chart
P/BV x 0.9 30.5 2.9% View Chart
Dividend Yield % 0.5 1.5 36.4%  

Financials

 STRIDES PHARMA SCIENCE   NOVARTIS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
NOVARTIS
Mar-18
STRIDES PHARMA SCIENCE/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,147758 151.3%   
Low Rs642579 110.9%   
Sales per share (Unadj.) Rs317.2228.4 138.9%  
Earnings per share (Unadj.) Rs7.831.7 24.7%  
Cash flow per share (Unadj.) Rs25.132.8 76.5%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.5 14.9%  
Book value per share (Unadj.) Rs274.3297.1 92.3%  
Shares outstanding (eoy) m89.5024.69 362.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.9 96.3%   
Avg P/E ratio x114.021.1 541.3%  
P/CF ratio (eoy) x35.720.4 175.0%  
Price / Book Value ratio x3.32.2 145.0%  
Dividend payout %25.531.5 80.9%   
Avg Mkt Cap Rs m80,05816,505 485.0%   
No. of employees `0002.50.7 375.3%   
Total wages/salary Rs m4,3411,445 300.3%   
Avg. sales/employee Rs Th11,325.88,441.3 134.2%   
Avg. wages/employee Rs Th1,731.42,163.6 80.0%   
Avg. net profit/employee Rs Th280.11,173.1 23.9%   
INCOME DATA
Net Sales Rs m28,3945,639 503.5%  
Other income Rs m9411,718 54.7%   
Total revenues Rs m29,3347,357 398.7%   
Gross profit Rs m3,965-63 -6,344.6%  
Depreciation Rs m1,54025 6,088.5%   
Interest Rs m1,96255 3,548.6%   
Profit before tax Rs m1,4031,575 89.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97792 12.3%   
Profit after tax Rs m702784 89.6%  
Gross profit margin %14.0-1.1 -1,260.0%  
Effective tax rate %6.950.3 13.8%   
Net profit margin %2.513.9 17.8%  
BALANCE SHEET DATA
Current assets Rs m24,8369,522 260.8%   
Current liabilities Rs m18,9933,296 576.2%   
Net working cap to sales %20.6110.4 18.6%  
Current ratio x1.32.9 45.3%  
Inventory Days Days7137 193.8%  
Debtors Days Days11328 399.0%  
Net fixed assets Rs m34,28946 74,540.9%   
Share capital Rs m895123 725.3%   
"Free" reserves Rs m23,6517,213 327.9%   
Net worth Rs m24,5467,336 334.6%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43711,105 589.3%  
Interest coverage x1.729.5 5.8%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 85.5%   
Return on assets %4.17.6 53.9%  
Return on equity %2.910.7 26.8%  
Return on capital %6.922.2 31.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69761 25,902.8%   
Fx outflow Rs m7353,630 20.3%   
Net fx Rs m14,962-3,570 -419.1%   
CASH FLOW
From Operations Rs m1,8711,610 116.2%  
From Investments Rs m5,826687 848.0%  
From Financial Activity Rs m-10,157-2,677 379.5%  
Net Cashflow Rs m-2,615-380 688.9%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 37.8 2.0 1,890.0%  
FIIs % 8.6 1.6 537.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.5 120.5%  
Shareholders   56,241 41,647 135.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PFIZER  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; FMCG and Banking Stocks Gain(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading up by 104 points and the NSE Nifty is trading up by 32 points.

Related Views on News

STRIDES PHARMA SCIENCE Plunges by 6%; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jul 17, 2019 | Updated on Jul 17, 2019

STRIDES PHARMA SCIENCE share price has plunged by 6% and its current market price is Rs 370. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 3.5%) and PFIZER (up 2.5%). The top losers is STRIDES PHARMA SCIENCE (down 5.6%)..

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 17, 2019 01:43 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - NATCO PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS